Literature DB >> 11965043

Depletion of recipient CD4+ but not CD8+ T lymphocytes prevents the development of cardiac allograft vasculopathy.

Wilson Y Szeto1, Alyssa M Krasinskas, Daniel Kreisel, Alexander S Krupnick, Sicco H Popma, Bruce R Rosengard.   

Abstract

BACKGROUND: We have described that chimeric rat hearts bearing recipient-type antigen-presenting cells (APCs) do not reject acutely, but develop cardiac allograft vasculopathy (CAV) in untreated recipients. This suggests that CAV is triggered either by CD8+ direct allorecognition or by CD4+ indirect allorecognition. To determine the allorecognition pathway responsible for CAV in this model, recipients of chimeric hearts underwent either CD8+ or CD4+ T cell depletion.
METHODS: Chimeric hearts were created via bone marrow transplantation in two fully major histocompatibility-mismatched rat strain combinations. DA recipients were thymectomized and treated with Ox8 and Ox38 murine monoclonal antibodies, which deplete CD8+ and CD4+ T cells, respectively. Chimeric PVG hearts bearing DA APCs, abbreviated PVG(DA), were heterotopically transplanted into recipients undergoing thymectomy alone or recipients undergoing thymectomy plus either CD4+ or CD8+ T cell depletion.
RESULTS: PVG(DA) allografts survived 100 days, but developed CAV in thymectomized recipients and in those permanently depleted of CD8+ T cells. In contrast, chimeric hearts transplanted into permanently CD4+ T cell-depleted recipients survived 100 days and demonstrated no evidence of CAV.
CONCLUSIONS: In this specific strain combination, recipient CD8+ T cells are neither necessary nor sufficient for the development of CAV, whereas recipient CD4+ T cells are required for the development of CAV. These findings suggest that CAV is dependent on CD4+ indirect allorecognition and that CD8+ direct allorecognition stimulated by nonprofessional APCs plays a minor role.

Entities:  

Mesh:

Year:  2002        PMID: 11965043     DOI: 10.1097/00007890-200204150-00019

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  A two-step model of acute CD4 T-cell mediated cardiac allograft rejection.

Authors:  Todd J Grazia; Biagio A Pietra; Zachary A Johnson; Brian P Kelly; Robert J Plenter; Ronald G Gill
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

2.  Expression of allograft inflammatory factor-1 in T lymphocytes: a role in T-lymphocyte activation and proliferative arteriopathies.

Authors:  Sheri E Kelemen; Michael V Autieri
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

Review 3.  Cardiac allograft vasculopathy: a review.

Authors:  Danny Ramzy; Vivek Rao; Julie Brahm; Santiago Miriuka; Diego Delgado; Heather J Ross
Journal:  Can J Surg       Date:  2005-08       Impact factor: 2.089

4.  Acute cardiac allograft rejection by directly cytotoxic CD4 T cells: parallel requirements for Fas and perforin.

Authors:  Todd J Grazia; Robert J Plenter; Sarah M Weber; Helen M Lepper; Francisco Victorino; Martin R Zamora; Biagio A Pietra; Ronald G Gill
Journal:  Transplantation       Date:  2010-01-15       Impact factor: 4.939

5.  Perforin mediates endothelial cell death and resultant transplant vascular disease in cardiac allografts.

Authors:  Jonathan C Choy; Alexandra Kerjner; Brian W Wong; Bruce M McManus; David J Granville
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

6.  Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.

Authors:  Huijun Ying; Hongmei Fu; Marlene L Rose; Ann M McCormack; Padmini Sarathchandra; Klaus Okkenhaug; Federica M Marelli-Berg
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

7.  Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice.

Authors:  James S Young; Stella H-W Khiew; Jinghui Yang; Augustin Vannier; Dengping Yin; Roger Sciammas; Maria-Luisa Alegre; Anita S Chong
Journal:  Front Immunol       Date:  2017-09-20       Impact factor: 7.561

8.  Small Molecule Tyrosine Kinase Inhibitor Nintedanib Reduces Development of Cardiac Allograft Vasculopathy in Murine Aortic Allografts.

Authors:  Annika Gocht; Bernd Spriewald; Jörg H W Distler; Martina Ramsperger-Gleixner; Stephan M Ensminger; Michael Weyand; Christian Heim
Journal:  Transplant Direct       Date:  2018-06-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.